BioWorld

Nov. 30, 2007

Regeneron Signs Sanofi To Potential $1B Collaboration

Regeneron Pharmaceuticals Inc. and Sanofi-Aventis are collaborating to discover, develop and commercialize human therapeutic antibodies in a cash and stock deal potentially worth $1 billion. (BioWorld Today) Read More

Axcan Goes Private Through $1.3B TPG Acquisition Deal

For Cardioprotection, Akt Is Not Sole Actor, Study Finds

Medgenics' IPO Pulls £3.28M To Advance Biopump Efforts

MGI Reviews Strategic Options; Stays Mum On Prospective Deals

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for Dec. 31, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 2, 2026.

AND-017 increases RBC and hemoglobin in sickle cell disease

BioWorld Science

Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...

Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact

BioWorld

Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...

Big pharma taps fast Asia innovation in search of next Keytruda

BioWorld

Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...